Dashboard
Manage Tickers

ESPR Esperion Therapeutics, Inc.

Nasdaq esperion.com


$ 3.11 $ 0.00 (0 %)    

Wednesday, 12-Nov-2025 07:07:20 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 625.32 $ 0.00 (0 %)
DIA $ 480.57 $ 0.00 (0 %)
SPY $ 685.31 $ 0.00 (0 %)
TLT $ 89.89 $ 0.00 (0 %)
GLD $ 379.62 $ 0.00 (0 %)
$ 3.1
$ 2.88
$ 3.10 x 3,089
$ 3.12 x 100
-- - --
$ 0.69 - $ 3.94
7,913,987
na
741.1M
$ 1.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-07-2025 01-01-1970 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-01-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 02-21-2023 12-31-2022 10-K
13 11-01-2022 09-30-2022 10-Q
14 08-02-2022 06-30-2022 10-Q
15 05-03-2022 03-31-2022 10-Q
16 02-22-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 02-23-2021 12-31-2020 10-K
21 11-02-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-01-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-02-2018 03-31-2018 10-Q
32 02-20-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 02-22-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-04-2016 03-31-2016 10-Q
40 02-25-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

esperion-presents-two-post-hoc-analyses-from-clear-outcomes-focused-on-mace-and-vte-at-aha-scientific-sessions-2025
Esperion Presents Two Post Hoc Analyses Fr...
11/10/2025 13:08:44

– Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced...

doordash-posts-downbeat-q3-earnings-joins-elf-beauty-duolingo-hubspot-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
DoorDash Posts Downbeat Q3 Earnings, Joins...
11/06/2025 13:27:03

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
11/06/2025 12:05:55

why-snap-shares-are-trading-higher-by-around-20-here-are-20-stocks-moving-premarket
Why Snap Shares Are Trading Higher By Arou...
11/06/2025 11:32:05

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

esperion-therapeutics-q3-eps-016-misses-008-estimate-sales-87309m-beat-77803m-estimate
Esperion Therapeutics Q3 EPS $(0.16) Misse...
11/06/2025 11:01:28

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate ...

esperion-to-present-new-clear-outcomes-data-on-bempedoic-acid-at-aha-2025-scientific-sessions
Esperion To Present New CLEAR Outcomes Dat...
10/27/2025 12:02:36

esperion-nominates-esp-2001-as-preclinical-development-candidate-for-primary-sclerosing-cholangitis
Esperion Nominates ESP-2001 As Preclinical...
10/16/2025 12:05:36

– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associate...

dow-jumps-over-100-points-us-crude-oil-inventories-increase
Dow Jumps Over 100 Points; US Crude Oil In...
10/08/2025 17:22:50

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/08/2025 17:06:09

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/08/2025 12:09:23

penguin-solutions-posts-q4-earnings-joins-esperion-therapeutics-joby-aviation-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Penguin Solutions Posts Q4 Earnings, Joins...
10/08/2025 12:01:10

why-confluent-shares-are-trading-higher-by-around-20-here-are-20-stocks-moving-premarket
Why Confluent Shares Are Trading Higher By...
10/08/2025 08:43:58

reported-earlier-esperion-therapeutics-prices-30m-common-share-offering-at-250-per-share-for-gross-proceeds-of-75m
Reported Earlier, Esperion Therapeutics Pr...
10/08/2025 06:55:52

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 21:06:58

esperion-announces-proposed-public-offering-of-common-stock-terms-not-disclosed
Esperion Announces Proposed Public Offerin...
10/07/2025 20:03:27

Esperion Therapeutics, Inc. ("Esperion") (NASDAQ:ESPR), a commercial stage biopharmaceutical company that focuses on de...

esperion-therapeutics-shares-halted-on-circuit-breaker-to-the-downside-stock-now-up-1603
Esperion Therapeutics Shares Halted On Cir...
10/03/2025 13:58:33

Core News & Articles
Esperion, Dr. Reddy's Laboratories Reach P...
10/03/2025 12:04:05

ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it has entered into a settlemen...

hc-wainwright--co-reiterates-buy-on-esperion-therapeutics-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Espe...
09/19/2025 13:23:32

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

esperions-nexletol-partner-otsuka-receives-approval-in-japan-to-market-nexletol-for-treatment-of-hypercholesterolemia
Esperion's NEXLETOL Partner, Otsuka, Recei...
09/19/2025 12:01:54

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION